JP2007530598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530598A5 JP2007530598A5 JP2007505270A JP2007505270A JP2007530598A5 JP 2007530598 A5 JP2007530598 A5 JP 2007530598A5 JP 2007505270 A JP2007505270 A JP 2007505270A JP 2007505270 A JP2007505270 A JP 2007505270A JP 2007530598 A5 JP2007530598 A5 JP 2007530598A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- phenyl
- independently
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 79
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims 23
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- 125000006573 (C1-C10) heteroaryl group Chemical group 0.000 claims 10
- 125000000304 alkynyl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- 239000000651 prodrug Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000003282 alkyl amino group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 5
- 125000003277 amino group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- -1 —N 3 Chemical group 0.000 claims 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 229910052757 nitrogen Chemical group 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 229920001774 Perfluoroether Chemical group 0.000 claims 3
- 206010040070 Septic Shock Diseases 0.000 claims 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 3
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 125000004104 aryloxy group Chemical group 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000004043 oxo group Chemical group O=* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006651 (C3-C20) cycloalkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000018652 Closed Head injury Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014824 Endotoxic shock Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 108060004872 MIF Proteins 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000025157 Oral disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010061494 Rhinovirus infection Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000010001 Silicosis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000005008 bacterial sepsis Diseases 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000030194 mouth disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000011164 ossification Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000004595 synovitis Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 0 *C(N(CC1)CCN1C(CC(C1)ON=C1c(cc1)ccc1O)=O)=O Chemical compound *C(N(CC1)CCN1C(CC(C1)ON=C1c(cc1)ccc1O)=O)=O 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55644004P | 2004-03-26 | 2004-03-26 | |
| PCT/US2005/010444 WO2005094329A2 (en) | 2004-03-26 | 2005-03-28 | Compouns, compositions, processes of making, and methods of use related to inhibiting macrophage migration inhibitory factor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007530598A JP2007530598A (ja) | 2007-11-01 |
| JP2007530598A5 true JP2007530598A5 (enExample) | 2008-05-15 |
Family
ID=35064296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505270A Pending JP2007530598A (ja) | 2004-03-26 | 2005-03-28 | マクロファージ遊走阻害因子の阻害に関する、化合物、組成物、作製プロセス、および使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20050250826A1 (enExample) |
| EP (1) | EP1727542A4 (enExample) |
| JP (1) | JP2007530598A (enExample) |
| CN (1) | CN101098697B (enExample) |
| AU (1) | AU2005228417A1 (enExample) |
| BR (1) | BRPI0507818A (enExample) |
| CA (1) | CA2557166C (enExample) |
| MX (1) | MXPA06010793A (enExample) |
| WO (1) | WO2005094329A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4883296B2 (ja) * | 2004-03-05 | 2012-02-22 | 日産化学工業株式会社 | イソキサゾリン置換ベンズアミド化合物及び有害生物防除剤 |
| TW200803740A (en) | 2005-12-16 | 2008-01-16 | Du Pont | 5-aryl isoxazolines for controlling invertebrate pests |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| US8362053B2 (en) | 2006-03-24 | 2013-01-29 | The Feinstein Institute For Medical Research | Modified macrophage migration inhibitory factor inhibitors |
| CN101815706A (zh) | 2007-06-13 | 2010-08-25 | 杜邦公司 | 异*唑啉杀昆虫剂 |
| TWI430995B (zh) | 2007-06-26 | 2014-03-21 | Du Pont | 萘異唑啉無脊椎有害動物控制劑 |
| MX2009013748A (es) | 2007-06-27 | 2010-01-26 | Du Pont | Metodo de control de plagas en animales. |
| TWI600639B (zh) | 2007-08-17 | 2017-10-01 | 杜邦股份有限公司 | 製備５-鹵烷基-４，５-二氫異唑衍生物之化合物 |
| JP5676262B2 (ja) | 2007-10-03 | 2015-02-25 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ | 有害無脊椎生物の防除用ナフタレンイソキサゾリン化合物 |
| TW201444787A (zh) | 2008-04-09 | 2014-12-01 | Du Pont | 製備３-三氟甲基查耳酮（ｃｈａｌｃｏｎｅ）之方法 |
| WO2010017132A1 (en) * | 2008-08-04 | 2010-02-11 | Chdi, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8927551B2 (en) | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8765735B2 (en) | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| WO2011066482A2 (en) * | 2009-11-25 | 2011-06-03 | Cytokine Pharmasciences, Inc. | Chiral synthesis of isoxazolines, isoxazoline compounds, and uses thereof |
| US20130196996A1 (en) * | 2010-01-19 | 2013-08-01 | Cpsi Stockholder Trust | Use of isoxazoline compounds and compositions in bladder cancer |
| PH12012502333A1 (en) | 2010-05-27 | 2015-02-04 | Corteva Agriscience Llc | Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide |
| EP2731970B1 (en) | 2011-07-15 | 2018-11-28 | MorphoSys AG | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| MY166890A (en) | 2011-08-30 | 2018-07-24 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9428464B2 (en) | 2011-08-30 | 2016-08-30 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| TW201348214A (zh) * | 2012-04-26 | 2013-12-01 | Toyama Chemical Co Ltd | 氘化含氮雜環羧醯胺衍生物 |
| WO2013184884A1 (en) | 2012-06-06 | 2013-12-12 | Basf Corporation | Improved methods for botanical and/or algae extraction |
| EP2944310B1 (en) | 2014-05-16 | 2018-03-21 | Mifcare | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension |
| JP2017520610A (ja) | 2014-07-17 | 2017-07-27 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | Ｈｉｖ関連障害を治療するための方法及び組成物 |
| US11397182B2 (en) | 2014-10-07 | 2022-07-26 | Cornell University | Methods for prognosing and preventing metastatic liver disease |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933464A (en) * | 1988-04-25 | 1990-06-12 | W. R. Grace & Co.-Conn. | Process for forming 3-phenylisoxazolines and 3-phenylisoxazoles |
| JP2787602B2 (ja) * | 1990-01-24 | 1998-08-20 | 大鵬薬品工業株式会社 | イソキサゾリン誘導体 |
| JP2738486B2 (ja) * | 1992-11-20 | 1998-04-08 | ファイザー製薬株式会社 | 抗炎症剤としての新規なイソオキサゾリン類 |
| JPH0741459A (ja) * | 1993-07-29 | 1995-02-10 | Sumitomo Pharmaceut Co Ltd | 新規エラスターゼ阻害剤 |
| US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| DE69422061T2 (de) * | 1993-11-26 | 2000-03-30 | Pfizer, Inc. | 3-phenyl-2-isoxazoline derivate als entzündugshemmende mittel |
| CA2176255C (en) * | 1993-11-26 | 1999-02-23 | Edward F. Kleinman | Isoxazoline compounds as antiinflammatory agents |
| KR100200449B1 (ko) * | 1994-03-09 | 1999-06-15 | 디. 제이. 우드, 스피겔 알렌 제이 | Tnf 방출 억제제로서의 이소옥사졸린 화합물 |
| US6420188B1 (en) * | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6492428B1 (en) * | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| FR2764889B1 (fr) * | 1997-06-20 | 2000-09-01 | Sod Conseils Rech Applic | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| US6335445B1 (en) * | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| AU1235601A (en) * | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| WO2002100332A2 (en) * | 2001-06-08 | 2002-12-19 | Cytokine Pharmasciences, Inc. | Isoxazoline compounds having mif antagonist activity |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| WO2005058845A2 (en) * | 2003-12-19 | 2005-06-30 | Novo Nordisk A/S | Novel glucagon antagonists/inverse agonists |
-
2005
- 2005-03-28 EP EP05742932A patent/EP1727542A4/en not_active Withdrawn
- 2005-03-28 BR BRPI0507818-0A patent/BRPI0507818A/pt not_active IP Right Cessation
- 2005-03-28 JP JP2007505270A patent/JP2007530598A/ja active Pending
- 2005-03-28 US US11/090,128 patent/US20050250826A1/en not_active Abandoned
- 2005-03-28 MX MXPA06010793A patent/MXPA06010793A/es active IP Right Grant
- 2005-03-28 AU AU2005228417A patent/AU2005228417A1/en not_active Abandoned
- 2005-03-28 CN CN2005800098795A patent/CN101098697B/zh not_active Expired - Fee Related
- 2005-03-28 CA CA2557166A patent/CA2557166C/en not_active Expired - Fee Related
- 2005-03-28 WO PCT/US2005/010444 patent/WO2005094329A2/en not_active Ceased
-
2007
- 2007-05-01 US US11/742,978 patent/US20080113997A1/en not_active Abandoned
-
2012
- 2012-09-25 US US13/626,816 patent/US20130225586A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007530598A5 (enExample) | ||
| JP6957518B2 (ja) | 感染症の治療のための酸素、硫黄および窒素リンカーを有する新規ピラジン化合物 | |
| KR101514866B1 (ko) | 티오펜 유도체 | |
| JP2008510762A5 (enExample) | ||
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| US20110160193A1 (en) | New Benzothiazinone Derivatives and Their Use as Antibacterial Agents | |
| JP2010540593A5 (enExample) | ||
| JP2011520815A5 (enExample) | ||
| JPH06507394A (ja) | 殺菌剤として置換−２−フェニル−３−メトキシプロペノエート | |
| CA2565660A1 (en) | Ortho substituted aryl or heteroaryl amide compounds | |
| JP2010502675A5 (enExample) | ||
| CN111655692B (zh) | 含氮杂环酰胺化合物及其医药用途 | |
| JP2009532417A5 (enExample) | ||
| JP2007524696A5 (enExample) | ||
| JP2007515432A5 (enExample) | ||
| RU2009139904A (ru) | Гидролитически устойчивые борсодержащие терапевтические агенты и способы их применения | |
| JP2010536829A5 (enExample) | ||
| JP2015500795A5 (enExample) | ||
| RU2012125971A (ru) | Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных | |
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| JP2013515037A5 (enExample) | ||
| ES2548258T3 (es) | Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1 | |
| JP2017534657A (ja) | 新型シチジン誘導体およびその適用 | |
| JP2018530582A5 (enExample) | ||
| JP2012524107A5 (enExample) |